Abivax S.A.(ABVX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ABVX Abivax S.A.

交易中 10-23 12:47:32 EDT

87.88

-2.35

-2.61%

最高89.60	最低87.28	成交量21.11万
今开89.60	昨收90.23	日振幅2.57%
总市值76.50亿	流通市值62.49亿	总股本8,705万
成交额1,860万	换手率0.30%	流通股本7,111万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ABVX","market":"US","secType":"STK","nameCN":"Abivax S.A.","latestPrice":87.875,"timestamp":1792774018776,"preClose":90.23,"halted":0,"volume":211119,"delay":0,"changeRate":-0.026099966751634753,"floatShares":71109800,"shares":87054500,"eps":-5.917616,"marketStatus":"交易中","change":-2.355,"latestTime":"10-23 12:47:32 EDT","open":89.6,"high":89.6,"low":87.28,"amount":18604559.97483,"amplitude":0.025712,"askPrice":87.95,"askSize":2,"bidPrice":87.76,"bidSize":130,"shortable":3,"etf":0,"ttmEps":-5.917616,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1792785600000},"marketStatusCode":2,"adr":0,"adrRate":1,"listingDate":1697774400000,"exchange":"NASDAQ","adjPreClose":90.23,"preHourTrading":{"tag":"盘前","latestPrice":89.49,"preClose":90.23,"latestTime":"09:28 EDT","volume":4842,"amount":437966.86509,"timestamp":1792762080001,"change":-0.74,"changeRate":-0.008201,"amplitude":0.013964},"postHourTrading":{"tag":"盘后","latestPrice":90.5,"preClose":90.23,"latestTime":"19:54 EDT","volume":2066,"amount":186592.3621,"timestamp":1792713293289,"change":0.27,"changeRate":0.002992,"amplitude":0.002992},"volumeRatio":0.321355,"impliedVol":0.7015,"impliedVolPercentile":0.1235},"requestUrl":"/m/hq/s/ABVX","defaultTab":"news","newsList":[{"id":"1184018309","title":"异动解读｜Abivax S.A.盘中下跌5.07%，目标价再遭下调压制情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1184018309","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184018309?lang=zh_cn&edition=full","pubTime":"2026-10-23 00:35","pubTimestamp":1792686920,"startTime":"0","endTime":"0","summary":"10月23日，Abivax S.A.盘中下跌5.07%，报88.77美元，成交额3885.06万美元。消息面上，Wedbush最新将公司目标价从118美元下调至96美元，并维持中性评级，延续了此前业绩披露后的谨慎预期。公司此前披露H1每股亏损2.43美元，明显差于市场预期，但销售额295.9万美元高于预期。尽管公司重申计划于年底前提交obefazimod用于中重度活动性溃疡性结肠炎的首项新药申请，市场短线仍在消化目标价下调带来的压力。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Abivax盘中下跌，目标价遭下调","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199679948","title":"异动解读｜Abivax S.A.盘中上涨5.2%，目标价再遭下调后市场仍聚焦核心管线价值","url":"https://stock-news.laohu8.com/highlight/detail?id=1199679948","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199679948?lang=zh_cn&edition=full","pubTime":"2026-10-20 22:53","pubTimestamp":1792507984,"startTime":"0","endTime":"0","summary":"10月20日，Abivax S.A.盘中上涨5.2%，报92.04美元，成交额5658.35万美元。消息面上，Wedbush最新将公司目标价从118美元下调至96美元，并维持中性评级；不过当前市场对公司核心候选药物obefazimod的后续申报与商业化前景仍保持关注。此前公司H1每股亏损2.43美元，明显差于市场预期，但销售额295.9万美元高于预期。公司重申计划于年底前提交obefazimod用于中重度活动性溃疡性结肠炎的首项新药申请，资金方面亦已获得较强支撑。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Abivax盘中上涨，核心管线申报在即","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137350494","title":"异动解读｜Abivax S.A.盘前下跌5.85%，H1业绩扰动与目标价下调余波仍在","url":"https://stock-news.laohu8.com/highlight/detail?id=1137350494","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137350494?lang=zh_cn&edition=full","pubTime":"2026-10-19 18:37","pubTimestamp":1792406229,"startTime":"0","endTime":"0","summary":"10月19日，Abivax S.A.盘前下跌5.85%，报83.12美元，成交额129.0万美元。消息面上，公司此前披露H1每股亏损2.43美元，明显差于市场预期的1.08美元，尽管销售额295.9万美元高于预期的186万美元，但业绩压力仍压制情绪。在业绩发布后，Wedbush将目标价从160美元下调至118美元并维持中性评级，Truist也同步下调目标价。公司核心候选药物obefazimod仍处于溃疡性结肠炎III期开发阶段，市场继续关注后续申报进度与商业化前景。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Abivax盘前走低，业绩疲软叠加目标价遭下调","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141620337","title":"异动解读｜Abivax S.A.盘中下跌5.07%，H1业绩扰动与目标价下调余波仍在","url":"https://stock-news.laohu8.com/highlight/detail?id=1141620337","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141620337?lang=zh_cn&edition=full","pubTime":"2026-10-17 01:09","pubTimestamp":1792170550,"startTime":"0","endTime":"0","summary":"10月17日，Abivax S.A.盘中下跌5.07%，报87.7美元，成交额5163.48万美元。消息面上，公司此前披露H1每股亏损2.43美元，明显差于市场预期的1.08美元，但销售额295.9万美元高于预期的186万美元；业绩发布后，Wedbush将目标价从160美元下调至118美元并维持中性评级，Truist也同步下调目标价，相关影响仍在消化。公司核心候选药物obefazimod仍处于溃疡性结肠炎III期开发阶段，市场继续关注其后续申报进度与商业化前景。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Abivax盘中下挫，业绩扰动余波未平","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125970500","title":"异动解读｜Abivax S.A.盘中上涨5.01%，H1业绩后目标价下调影响渐消","url":"https://stock-news.laohu8.com/highlight/detail?id=1125970500","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125970500?lang=zh_cn&edition=full","pubTime":"2026-10-15 22:18","pubTimestamp":1792073928,"startTime":"0","endTime":"0","summary":"10月15日，Abivax S.A.盘中上涨5.01%，报91.885美元，成交额2970.38万美元。近期可对应的公开消息是，公司此前披露H1每股亏损2.43美元，明显低于市场预期的1.08美元，但销售额295.9万美元高于预期的186万美元；随后Wedbush将目标价从160美元下调至118美元并维持中性评级，Truist也下调目标价。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Abivax股价上扬，新药申请临近催化","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196514249","title":"异动解读｜Abivax S.A.盘中下跌5.18%，财报不及预期叠加机构下调评级持续承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1196514249","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1196514249?lang=zh_cn&edition=full","pubTime":"2026-10-01 22:39","pubTimestamp":1790865589,"startTime":"0","endTime":"0","summary":"10月1日，Abivax S.A.盘中下跌5.18%，报93.89美元/股，成交额2931.93万美元。财报发布后，Wedbush将目标价从160美元下调至118美元，Truist下调至151美元；此后Wall Street Zen进一步将评级由\"持有\"下调至\"卖出\"，多重利空持续压制股价表现。Abivax S.A.是一家临床阶段的生物技术公司，专注于开发利用人体自然调节机制来稳定慢性炎症性疾病免疫反应的疗法，其核心候选药物obefazimod正处于治疗溃疡性结肠炎的3期开发阶段，公司计划于年底前提交新药上市申请。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"财报巨亏叠加评级下调，Abivax承压走低","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121989318","title":"异动解读｜Abivax S.A.盘中上涨5.1%，报95.705美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1121989318","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121989318?lang=zh_cn&edition=full","pubTime":"2026-09-28 22:25","pubTimestamp":1790605540,"startTime":"0","endTime":"0","summary":"9月28日，Abivax S.A.盘中上涨5.1%，报95.705美元/股，成交额4374.82万美元。Abivax S.A.所在的生物科技行业中，个股表现分化，其中Kodiak Sciences Inc.涨153.06%，Moderna, Inc.跌2.6%，安进跌0.14%，吉利德科学跌0.25%，再生元制药公司跌3.45%。Abivax S.A.是一家临床阶段的生物技术公司，专注于开发利用人体自然调节机制来稳定慢性炎症性疾病免疫反应的疗法，其主要候选药物obefazimod正处于治疗溃疡性结肠炎的3期开发阶段，公司计划于年底前提交新药上市申请。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174215564","title":"异动解读｜Abivax S.A.盘中下跌5.28%，上半年每股亏损大幅不及预期持续承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1174215564","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174215564?lang=zh_cn&edition=full","pubTime":"2026-09-24 00:51","pubTimestamp":1790182273,"startTime":"0","endTime":"0","summary":"9月23日，Abivax S.A.盘中下跌5.28%，报93.1美元/股，成交额1.13亿美元。尽管销售额295.9万美元超出预期186万美元，但巨额亏损引发持续抛压。此外，公司宣布首席医疗官Fabio Cataldi将于第四季度离任，由Chris Rabbat接任，管理层变动进一步加剧市场不确定性。Abivax S.A.是一家临床阶段生物科技公司，核心候选药物obefazimod正处于治疗溃疡性结肠炎的3期开发阶段，公司计划于年底前提交新药上市申请。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Abivax亏损远超预期，盘中承压下跌","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199623756","title":"异动解读｜Abivax S.A.盘中下跌5.47%，上半年每股亏损大幅不及预期引发分析师下调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1199623756","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199623756?lang=zh_cn&edition=full","pubTime":"2026-09-22 21:46","pubTimestamp":1790084808,"startTime":"0","endTime":"0","summary":"9月22日，Abivax S.A.盘中下跌5.47%，报97.795美元/股，成交额2800.2万美元。消息面上，公司公布上半年财报，每股亏损2.43美元，远超市场预期的亏损1.08美元，偏差幅度达125%，较去年同期每股亏损1.47美元进一步扩大65.31%。尽管收入端表现尚可，但亏损大幅超预期引发市场担忧。Abivax S.A.是一家临床阶段生物科技公司，专注于开发利用人体自然调节机制稳定慢性炎症性疾病免疫反应的疗法，核心候选药物obefazimod正处于治疗溃疡性结肠炎的3期开发阶段。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"亏损远超预期，Abivax遭投行下调目标价","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194775209","title":"异动解读｜Abivax S.A.盘中上涨5.06%，机构看多叠加管线进展提振反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1194775209","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194775209?lang=zh_cn&edition=full","pubTime":"2026-09-17 23:39","pubTimestamp":1789659563,"startTime":"0","endTime":"0","summary":"9月17日，Abivax S.A.盘中上涨5.06%，报107.4美元/股，成交额4550.79万美元。此前公司股价因财报营收预计下降逾四成的预期一度下挫超5%，本次反弹或受机构看多观点及核心管线积极进展提振。公司已明确计划于年底前向监管机构提交obefazimod首项新药申请，同时已完成约9.2亿美元ADS发行，净募资约8.74亿美元，可支持运营至2029年第四季度，现金流安全边际充裕。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"大摩上调目标价，管线进展催化反弹","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191502299","title":"异动解读｜Abivax S.A.盘中下跌5.33%，财报前瞻显示营收预计降逾四成","url":"https://stock-news.laohu8.com/highlight/detail?id=1191502299","media":"行情直击","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191502299?lang=zh_cn&edition=full","pubTime":"2026-09-15 22:05","pubTimestamp":1789481124,"startTime":"0","endTime":"0","summary":"9月15日，Abivax S.A.盘中下跌5.33%，报107.6美元/股，成交额3131.06万美元。消息面上，公司将于9月21日盘后发布财报，市场一致预期显示本季度营收约67.89万欧元，同比下降43.05%；调整后每股亏损预计为1.06欧元，同比扩大33.33%；息税前利润预计为-5559.27万欧元，同比收窄15.29%。财报发布在即，营收大幅下滑的预期或令部分资金选择提前离场观望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"财报在即营收预降，Abivax盘中承压","news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197355785","title":"财报前瞻｜Abivax S.A.本季度营收预计降43.05%，机构观点偏多","url":"https://stock-news.laohu8.com/highlight/detail?id=1197355785","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197355785?lang=zh_cn&edition=full","pubTime":"2026-09-14 08:01","pubTimestamp":1789344111,"startTime":"0","endTime":"0","summary":"Abivax S.A.将于2026年09月21日（盘后）发布财报，市场关注亏损收窄节奏、现金流安全边际及核心管线进度。市场一致预期显示，本季度Abivax S.A.营收预计为67.89万欧元，同比-43.05%；调整后每股收益预计为-1.06欧元，同比变动-33.33%；息税前利润预计为-5,559.27万欧元，同比收窄15.29%。上季度Abivax S.A.营收为99.40万欧元，同比0.00%；毛利率为100.00%；归属母公司股东的净利润为-4,846.80万欧元；调整后每股收益为-0.61欧元，同比变动+26.51%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"财报前瞻｜Abivax S.A.本季度营收预计降43.05%，机构观点偏多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192804453","title":"Abivax S.A.：按计划推进，2026年底前提交Obefazimod治疗中重度活动性溃疡性结肠炎首项新药申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1192804453","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192804453?lang=zh_cn&edition=full","pubTime":"2026-07-31 04:13","pubTimestamp":1785442392,"startTime":"0","endTime":"0","summary":"Abivax S.A. 正稳步推进其研发管线。该公司重申，其目标明确——计划于2026年底前，正式向监管机构提交Obefazimod的首项新药申请（NDA）。这项申请旨在寻求该药物用于治疗中重度活动性溃疡性结肠炎（UC）的上市许可。这一进展，标志着公司在关键临床项目上迈出了坚实的一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100782164","title":"异动解读｜Abivax盘中上涨5.18%，摩根士丹利大幅上调目标价至180美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1100782164","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100782164?lang=zh_cn&edition=full","pubTime":"2026-07-30 23:00","pubTimestamp":1785423618,"startTime":"0","endTime":"0","summary":"7月30日，Abivax盘中上涨5.18%，报124.295美元/股，成交额5488.63万美元。消息面上，摩根士丹利近日发布研报，将Abivax目标价从132美元大幅上调至180美元，维持\"增持\"评级。此外，此前市场对标签限制及监管风险的担忧已随临床数据改善而缓解。公司7月初完成约9.2亿美元ADS发行，资金可支撑运营至2029年第四季度，为obefazimod美国商业化提供充足弹药。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114490786","title":"异动解读｜Abivax S.A.盘前上涨6.46%，9.2亿美元增发正式交割提振持续做多情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1114490786","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1114490786?lang=zh_cn&edition=full","pubTime":"2026-07-06 16:06","pubTimestamp":1783325216,"startTime":"0","endTime":"0","summary":"7月6日，Abivax S.A.盘前上涨6.46%，报152.5美元/股，成交额58.0万美元。消息面上，公司此前宣布承销商全额行使超额配售权，额外购入96万股ADS，总募资规模从8亿美元扩大至约9.2亿美元，净募集资金约8.74亿美元，该发行于本周一正式完成交割。此前公司公布ABTECT维持试验Part 2积极数据消除安全性争议，叠加发行规模由最初6亿美元两度上调并获超额配售全额认购，机构需求旺盛持续强化市场信心，股价维持在125美元发行价上方运行。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165938491","title":"异动解读｜Abivax S.A.夜盘上涨5.74%，9.2亿美元增发正式交割提振持续做多情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1165938491","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165938491?lang=zh_cn&edition=full","pubTime":"2026-07-06 15:01","pubTimestamp":1783321284,"startTime":"0","endTime":"0","summary":"7月6日，Abivax S.A.夜盘上涨5.74%，报152.96美元/股，成交额100.17万美元。消息面上，公司此前宣布承销商全额行使超额配售权，额外购入96万股ADS，总募资规模从8亿美元扩大至约9.2亿美元，净募集资金约8.74亿美元，该发行于本周一正式完成交割。此前公司公布ABTECT维持试验Part 2积极数据，消除安全性争议后股价已大幅反弹，叠加发行规模由最初6亿美元两度上调并获超额配售全额认购，机构需求旺盛持续强化市场信心，股价维持在125美元发行价上方运行。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189220198","title":"异动解读｜Abivax S.A.盘中上涨5.39%，承销商全额行使超额配售权总募资扩至9.2亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1189220198","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1189220198?lang=zh_cn&edition=full","pubTime":"2026-07-02 21:36","pubTimestamp":1782999412,"startTime":"0","endTime":"0","summary":"7月2日，Abivax S.A.盘中上涨5.39%，报140.67美元/股，成交额6686.63万美元。消息面上，公司宣布其ADS公开发行的承销商已全额行使超额配售权，额外购买96万股ADS，总募集金额从8亿美元提升至约9.2亿美元，预计下周一完成交割。此前公司公布ABTECT维持试验积极数据消除安全性争议，股价已大幅反弹，当前股价持续高于每股125美元的发行价运行，超额配售全额行使进一步强化市场信心。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123159008","title":"异动解读｜Abivax S.A.盘前上涨6.27%，8亿美元增发定价完成后市场追捧延续","url":"https://stock-news.laohu8.com/highlight/detail?id=1123159008","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123159008?lang=zh_cn&edition=full","pubTime":"2026-07-02 16:05","pubTimestamp":1782979503,"startTime":"0","endTime":"0","summary":"7月2日，Abivax S.A.盘前上涨6.27%，报140.88美元/股，成交额42.52万美元。消息面上，公司完成8亿美元ADS公开发行定价，以每股125美元发行640万股美国存托凭证，发行规模从此前的6亿美元上调至8亿美元，显示机构认购需求旺盛。募集资金将主要用于核心药物obefazimod在美国的商业化推进及溃疡性结肠炎和克罗恩病的临床研发。此前公司公布ABTECT维持试验积极数据消除安全性争议，股价已大幅反弹超38%，本次增发超额扩容进一步确认市场信心，当前股价持续高于发行价运行。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140015042","title":"异动解读｜Abivax S.A.夜盘上涨6.37%，8亿美元增发定价完成后市场追捧延续","url":"https://stock-news.laohu8.com/highlight/detail?id=1140015042","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1140015042?lang=zh_cn&edition=full","pubTime":"2026-07-02 15:05","pubTimestamp":1782975924,"startTime":"0","endTime":"0","summary":"7月2日，Abivax S.A.夜盘上涨6.37%，报141.0美元/股，成交额41.41万美元。消息面上，公司完成8亿美元ADS公开发行定价，以每股125美元发行640万股美国存托凭证，发行规模从此前的6亿美元上调至8亿美元，显示机构认购需求旺盛。募集资金将主要用于核心药物obefazimod在美国的商业化推进及溃疡性结肠炎和克罗恩病的临床研发。此前公司公布ABTECT维持试验积极数据消除安全性争议，股价已大幅反弹超38%，本次增发超额扩容进一步确认市场信心，当前股价持续高于发行价运行。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150042476","title":"异动解读｜Abivax S.A.盘中上涨36.68%，三期维持试验补充数据积极消除安全性争议","url":"https://stock-news.laohu8.com/highlight/detail?id=1150042476","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150042476?lang=zh_cn&edition=full","pubTime":"2026-06-30 21:31","pubTimestamp":1782826310,"startTime":"0","endTime":"0","summary":"6月30日，Abivax S.A.盘中上涨36.68%，报131.53美元/股，成交额1.81亿美元。此前50mg组曾因报告多例癌症病例致股价从130美元附近暴跌至约70美元，本次数据消除安全性新增隐患，前期争议逐步消化，多头情绪加速升温。此外，Wedbush将目标价从90美元上调至110美元。公司表示仍计划于第四季度向FDA提交新药上市申请。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.abivax.com","stockEarnings":[{"period":"1week","weight":-0.0233},{"period":"1month","weight":-0.082},{"period":"3month","weight":-0.2822},{"period":"6month","weight":-0.2124},{"period":"1year","weight":-0.0053},{"period":"ytd","weight":-0.3309}],"compareEarnings":[{"period":"1week","weight":-0.0101},{"period":"1month","weight":-0.0122},{"period":"3month","weight":0.0339},{"period":"6month","weight":0.0701},{"period":"1year","weight":0.144},{"period":"ytd","weight":0.1203}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Abivax Sa是一家于2013年12月4日根据法国法律注册成立。该公司是一家临床阶段的生物技术公司，专注于开发利用人体自然调节机制来稳定慢性炎症性疾病免疫反应的疗法。其主要候选药物obefazimod正处于治疗溃疡性结肠炎的3期开发阶段，并正在开发用于克罗恩病。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.04281},{"month":2,"riseRate":1,"avgChangeRate":0.136479},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.072201},{"month":4,"riseRate":1,"avgChangeRate":0.080768},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.030414},{"month":6,"riseRate":0.666667,"avgChangeRate":0.073267},{"month":7,"riseRate":0.333333,"avgChangeRate":2.737486},{"month":8,"riseRate":0.666667,"avgChangeRate":0.033214},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.053208},{"month":10,"riseRate":0.333333,"avgChangeRate":0.004474},{"month":11,"riseRate":0.666667,"avgChangeRate":0.049539},{"month":12,"riseRate":0.666667,"avgChangeRate":-0.002452}],"exchange":"NASDAQ","name":"Abivax S.A.","nameEN":"Abivax S.A."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Abivax S.A.(ABVX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Abivax S.A.(ABVX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Abivax S.A.,ABVX,Abivax S.A.股票,Abivax S.A.股票老虎,Abivax S.A.股票老虎国际,Abivax S.A.行情,Abivax S.A.股票行情,Abivax S.A.股价,Abivax S.A.股市,Abivax S.A.股票价格,Abivax S.A.股票交易,Abivax S.A.股票购买,Abivax S.A.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Abivax S.A.(ABVX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Abivax S.A.(ABVX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}